Trial Profile
Phase I study of Wilm's tumor gene WT1 peptide pulsed dendritic cell vaccination combined with gemcitabine for patients with advanced pancreatic cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 May 2016
Price :
$35
*
At a glance
- Drugs Tumour peptide-loaded dendritic cell vaccine Tella (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- 09 May 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 10 Jan 2013 Planned End Date 1 Mar 2013 added as reported by University Hospital Medical Information Network - Japan.
- 21 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.